EmailHospital Circular 23/2007
Date issued: 28 November 2007
Distribution: Public hospitals
Subject: Highly Specialised Drugs Program
Purpose: To advise hospitals of changes to the Highly Specialised Drugs Program, effective 1 December 2007
We have had recent advice from the Commonwealth Government of changes to the Highly Specialised Drugs Program, effective 1 December 2007.
ADDED ITEMS
| Darunavir | |||||
| 9616D | 300mg Tablet (as ethanolate) | 120 | Prezista | $1,101.38 | JC |
Infliximab |
|||||
| 9617E | (Adult patients with severe chronic plaque psoriasis) Powder for I.V. infusion 100mg (as sulfate) |
1 | Remicade | $751.70 | SH |
Full prescribing criteria for all items available at the Commonwealth/State Highly Specialised Drugs Program Guidelines website.
ADDED BRAND
| Octreotide acetate | ||||
| 6227R | Injection 50mcg (base) in 1 ml | 5 | $36.54 | MX |
| 6228T | Injection 100mcg (base) in 1 ml | 5 | $73.06 | MX |
| 6229W | Injection 500mcg (base) in 1 ml | 5 | $365.72 | MX |
PRICE DECREASE
| Octreotide acetate | |||||
| 6227R | Injection 50mcg (base) in 1 ml | 5 | Sandostatin 0.05 | $36.54 | NV |
| 6228T | Injection 100mcg (base) in 1 ml | 5 | Sandostatin 0.1 | $73.06 | NV |
| 6229W | Injection 500mcg (base) in 1 ml | 5 | Sandostatin 0.5 | $365.72 | NV |
AMENDED RESTRICTION
| Pegfilgrastim | |||||
| 6363X | Injection 6mg in 0.6ml | 1 | Neulasta | $1,925.00 | AN |
(g) non-Hodgkin’s lymphoma (intermediate or high grade; low grade receiving an anthracycline-containing regimen);
Changes notified by hospital circular will be updated in the Guidelines on the Commonwealth/State Highly Specialised Drugs Program Guidelines website and the claim form amended.
Approved by
Geoff Lavender
Director, Programs
Metropolitan Health & Aged Care Services
